Fanconi AnemiaNCT06490510
Prognostic Significance of Mutation Type and Chromosome Fragility in Fanconi Anemia
An observational study of Fanconi Anemia, run by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau at 1 site in Spain.
Trial summary
The goal of this observational study is to analyze the data included in the Spanish Registry of Patients with Fanconi anemia to better understand the natural history of the disease, identify genetic risk and prognostic factors, and identify potential therapeutic strategies. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Fanconi Anemia
- How many people
- 227 participants
- Where
- 1 siteSpain
- Study dates
- 16 May 2024to 18 Jun 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients with Fanconi anemia included in the Spanish Registry
Who may be able to join
- All patients in the Spanish Registry of Patients with Fanconi Anemia
Who cannot join
- -
Trial locations and contacts
1 site in 1 country.
Spain1 site
Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau - IIB Sant Pau
Barcelona, 08041
About this study
The goal of this observational study is to analyze the data included in the Spanish Registry of Patients with Fanconi anemia to better understand the natural history of the disease, identify genetic risk and prognostic factors, and identify potential therapeutic strategies.
- Conditions
- Fanconi Anemia
- Medical subject headings
- Fanconi Anemia
What is being measured
The primary outcome is the main question the study is designed to answer.
Description of the clinical evolution of the patient
Study the clinical evolution of patients with Fanconi anemia
Measured: 1 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jul 2024
- Study start16 May 2024
- Primary completion18 Jun 2024
- Study completion18 Jun 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Fanconi AnemiaStudies of the same condition, open and under way.
- More trials run by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 227 participants (actual)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jordi Surrallés, PhD, Principal investigator, Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06490510
- Sponsor's protocol ID
- IIBSP-PFA-2024-47
- Status last verified
- Jun 2024
- First submitted
- 17 May 2024
- Last updated
- 8 Jul 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Ramirez MJ, Pujol R, Minguillon J, Bogliolo M, Persico I, Cavero D, de la Cal A, Rio P, Navarro S, Casado JA, Bailador A, de la Fuente AS, de Heredia ML, Almazan F, Antelo ML, Argiles B, Badell I, Baragano M, Belendez C, Bermudez M, Bernues M, Buedo MI, Carrasco E, Catala A, Costa D, Cuesta I, Fernandez-Delgado R, Fernandez-Teijeiro A, Figuera A, Garcia M, Gondra A, Gonzalez M, Muniz SG, Hernandez-Rodriguez I, Ibanez F, Kelleher NJ, Lendinez F, Lopez M, Lopez-Almaraz R, Marchante I, Mendoza C, Nieto J, Ojeda E, Payan-Pernia S, Pelaez I, de Soto IP, Portugal R, Ramos-Arroyo MA, Regueiro A, Rodriguez A, Rosell J, Saez R, Sanchez J, Sanchez M, Senent M, Tapia M, Trujillo-Quintero JP, Vagace JM, Verdu-Amoros J, Verdugo V, Vidales I, Villarreal J, Diaz-de-Heredia C, Sevilla J, Bueren JA, Surralles J. Prognostic significance of mutation type and chromosome fragility in Fanconi anemia. Am J Hematol. 2025 Feb;100(2):272-284. doi: 10.1002/ajh.27520. Epub 2024 Nov 19.
PubMed 39562502
Study at a glance
From the registry record, last updated by the sponsor on 8 Jul 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prognostic Significance of Mutation Type and Chromosome Fragility in Fanconi Anemia
- ClinicalTrials.gov ID
- NCT06490510
- Acronym / sponsor ID
- IIBSP-PFA-2024-47
- Conditions
- Fanconi Anemia
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 227 participants (actual)
- Lead sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauUniversity, hospital or other
- Study start
- 16 May 2024 (actual)
- Primary completion
- 18 Jun 2024 (actual)
- Study completion
- 18 Jun 2024 (actual)
- First posted
- 8 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to analyze the data included in the Spanish Registry of Patients with Fanconi anemia to better understand the natural history of the disease, identify genetic risk and prognostic factors, and identify potential therapeutic strategies.
Study design
- Observational model
- Cohort
- Time perspective
- Other
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients with Fanconi anemia included in the Spanish Registry
Key inclusion criteria (1 listed)
- All patients in the Spanish Registry of Patients with Fanconi Anemia
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Description of the clinical evolution of the patient
Time frame: 1 month
Study the clinical evolution of patients with Fanconi anemia
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jul 2024.
- Derived from this study: PubMed 39562502Ramirez MJ, Pujol R, Minguillon J, Bogliolo M, Persico I, Cavero D, de la Cal A, Rio P, Navarro S, Casado JA, Bailador A, de la Fuente AS, de Heredia ML, Almazan F, Antelo ML, Argiles B, Badell I, Baragano M, Belendez C, Bermudez M, Bernues M, Buedo MI, Carrasco E, Catala A, Costa D, Cuesta I, Fernandez-Delgado R, Fernandez-Teijeiro A, Figuera A, Garcia M, Gondra A, Gonzalez M, Muniz SG, Hernandez-Rodriguez I, Ibanez F, Kelleher NJ, Lendinez F, Lopez M, Lopez-Almaraz R, Marchante I, Mendoza C, Nieto J, Ojeda E, Payan-Pernia S, Pelaez I, de Soto IP, Portugal R, Ramos-Arroyo MA, Regueiro A, Rodriguez A, Rosell J, Saez R, Sanchez J, Sanchez M, Senent M, Tapia M, Trujillo-Quintero JP, Vagace JM, Verdu-Amoros J, Verdugo V, Vidales I, Villarreal J, Diaz-de-Heredia C, Sevilla J, Bueren JA, Surralles J. Prognostic significance of mutation type and chromosome fragility in Fanconi anemia. Am J Hematol. 2025 Feb;100(2):272-284. doi: 10.1002/ajh.27520. Epub 2024 Nov 19.
Related trials for Fanconi Anemia
RecruitingObservational study
Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia
Fanconi Anemia, Inherited Bone Marrow Failure Syndrome
Not yet recruitingObservational study
Clinical Genetics Branch Eligibility Screening Survey
Melanoma, Li-Fraumeni Syndrome
RecruitingObservational study
Cancer in Inherited Bone Marrow Failure Syndromes
Diamond Blackfan Anemia, Dyskeratosis Congenita
RecruitingObservational study
Accuracy of Home Lactate Meter and Accu-chek Glucometer in Patients With Glycogen Storage Disease
Glycogen Storage Disease Type IA, Glycogen Storage Disease Type I
RecruitingPhase 1
Safety and Tolerability of Metformin and Naproxen for Cancer Prevention in Fanconi Anemia
Fanconi Anemia, Head and Neck Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jordi Surrallés, PhD principal investigator
Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Fanconi Anemia, run by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Description of the clinical evolution of the patient (time frame: 1 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06490510, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jul 2024.